CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd.
Your view on CLGN
Overview
What the company does, where it operates, and who runs it.
About CollPlant Biotechnologies Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yehiel Tal
- Headquarters
- Weizmann Science Park, Rehovot, IL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yehiel Tal
- Headquarters
- Weizmann Science Park, Rehovot, IL
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe.
Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds.
It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL.
The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for CollPlant Biotechnologies Ltd., and the rating behind it. CLGN last traded at $3.54; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for CollPlant Biotechnologies Ltd.. Starting points for CollPlant Biotechnologies Ltd.: EPS -$9.55, beta 0.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for CollPlant Biotechnologies Ltd.. CollPlant Biotechnologies Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for CollPlant Biotechnologies Ltd.. Trailing twelve-month EPS for CollPlant Biotechnologies Ltd. stands at -$9.55. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for CollPlant Biotechnologies Ltd.. CollPlant Biotechnologies Ltd. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
CollPlant Biotechnologies Ltd. valued side by side against its closest peers. CollPlant Biotechnologies Ltd. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold CollPlant Biotechnologies Ltd., and how their positions are changing. At a $4.6M market value, institutional positions materially move CollPlant Biotechnologies Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by CollPlant Biotechnologies Ltd. executives and directors. Shares of CollPlant Biotechnologies Ltd. have traded between $1.31 and $4.98 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming CollPlant Biotechnologies Ltd.. CollPlant Biotechnologies Ltd. is a $4.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming CollPlant Biotechnologies Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for CollPlant Biotechnologies Ltd.. Coverage tracks CollPlant Biotechnologies Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.